Ceftolozane Tazobactam Linked to Increased Clinical Success in Pneumonia
The CACTUS study found a 10% improvement in clinical success with ceftolozane tazobactam (CT), which was linked to a 1.5-fold increased chance of clinical success. After adjusting for residual differences between the treatment arms, the likelihood of success was nearly twice as high with CT. Despite these findings, mortality rates were similar between the two […]
Identifying a Novel Variant of Klebsiella Pneumoniae
Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS, medical director for the microbiology laboratory at AdventHealth in Orlando, FL has a unique perspective. As someone who has been both a practicing physician in the past and a current laboratorian, he is able to utilize both his clinical and diagnostic experiences and apply them to […]
Examining COVID-19 Mortality Rates Against Specific Treatments for Inpatients
Image credit: Pexels-rdne As COVID-19 becomes an endemic respiratory pathogen we ultimate contend with, the capacity to treat and manage severe infections and reduce mortality is that much more important. The Centers for Disease Control and Prevention (CDC) noted an age-adjusted 47% decline in deaths from 2021 (when the first vaccines were rolled out) to […]
Contagion Winter 2024 Digital Edition
View our interactive Winter 2024 digital edition. Source link
CDC Report and RECOVER Study Update
Prevalences of current Long COVID (A) and significant Long COVID–associated activity limitation (B) among adults, by jurisdiction — Behavioral Risk Factor Surveillance System, United States, 2023 Image credits: CDC A new report from the CDC, based on data from the 2023 Behavioral Risk Factor Surveillance System (BRFSS), shows that 6.4% of noninstitutionalized US adults reported […]
PCR Testing Linked to Better Outcomes in Complicated UTI than Culture/Sensitivity-Guided Treatment
Image Credit: Valiantsin, Adobe Stock PCR-based molecular testing was associated with better clinical outcomes in complicated urinary tract infection (cUTI) than traditional culture-sensitivity in a randomized controlled trial, attributed by the investigators to enabling earlier targeted, rather than empiric treatment.1 “Our findings demonstrate a significantly faster turnaround time with molecular testing compared to C&S,” remarked […]
Top 5 Infectious Disease News Stories Week of December 14-20
This week, recent studies show progress in healthcare, including an mRNA vaccine for C difficile, the rise of antimicrobial resistance, peer-assisted telemedicine for hepatitis C in rural areas, and more. Source link
Gilead Submits FDA New Drug Application for Lenacapavir for HIV Prevention
Yesterday, Gilead announced it had submitted its new drug application (NDA) for its therapy, lenacapavir, for pre-exposure prophylaxis (PrEP) for HIV infection. The NDA is supported from data provided from the company’s phase 3 PURPOSE 1 and PURPOSE 2 trials. The PURPOSE 1 data showed twice-yearly lenacapavir demonstrated zero infections in the lenacapavir group and […]
The Slow-Moving Antimicrobial Resistance Train is Picking-up Morbidity and Mortality Steam
Antimicrobial resistance (AMR) is a slow-moving train that is picking up steam and in its path are all patients battling bacterial infections. AMR is a multifactorial problem that includes many aspects, and potentially chief among them is the missing communication and disconnect with the public, who do not understand the nature of how it happens […]
CACTUS Study Compares Ceftolozane-Tazobactam vs. Ceftazidime-Avibactam for MDR Pseudomonas
A newly published study, the CACTUS Study, compares the effectiveness of ceftolozane-tazobactam (CT) and ceftazidime-avibactam (CZA) in treating multidrug-resistant (MDR) Pseudomonas aeruginosa infections. The findings show that CT and CZA have similar clinical outcomes: 62% of CT-treated patients achieved clinical success, compared to 55% of CZA-treated patients. The overall 30-day mortality rates were also similar: […]
